Why Most Brain Supplements Don't Work

The brain-supplement market is projected to reach $23.5 billion by 2030. Millions of people will buy a nootropic this year hoping to sharpen memory, cut through brain fog, or stay mentally sharp as they age. Most of them will be disappointed, and the reason has nothing to do with whether brain supplements can work.

The science behind cognitive supplementation is real. Dozens of peer-reviewed trials show that specific compounds, at specific doses, can measurably improve memory, attention, and other measures of cognitive function. The problem isn't the science. The problem is what the industry does with it.

This article breaks down exactly why most brain supplements fail, the specific tricks companies use to sell you underdosed formulas, and how to identify the rare products actually built on real evidence.

The hidden-dose problem

The single biggest red flag in the industry isn't a word on a label. It's a number that isn't there.

Under FDA labeling rules (21 CFR 101.36), manufacturers can group ingredients under one blend name and disclose only the total weight. The individual amounts vanish. This is legal, and it's the primary mechanism companies use to sell formulas where the most important ingredients are barely present. Insiders call it "fairy dusting."

The problem is never the grouping. It's the missing numbers. A label can group three ingredients under one heading and still print all three amounts, and then you know exactly what you're buying. Novium-9's label does that: Ginkgo, Phosphatidylserine, and PQQ sit together under one heading, and all three amounts are printed individually, on the bottle and on our ingredients page. Grouping a heading is not the same as hiding a dose. Ask for the numbers, not the vocabulary.

The math never works. If a blend totals 1,200 mg and contains 10+ ingredients, most are present in amounts too small to produce any biological effect. Bacopa's memory trials used 300 mg of standardized extract; ashwagandha's cortisol trials used 600 mg. You cannot fit meaningful doses of both, plus eight more ingredients, into 1,200 mg.

Clinical doses vs. what you're actually getting

Even without a blend name to hide behind, most supplements contain ingredients at fractions of the proven doses. This is the difference between "clinically studied" and "clinically dosed," and it's where most brain supplements quietly fail.

So where does Novium-9 land? At the labeled two-capsule serving: Bacopa 300 mg, Ashwagandha 300 mg, Citicoline 250 mg, Ginkgo 120 mg, Phosphatidylserine 100 mg. Every one clears its clinical-effective minimum, and Bacopa sits at the full trial dose.

We also built the formula so you can double it. At four capsules, Ashwagandha reaches 600 mg, Citicoline 500 mg, and Ginkgo 240 mg, which are the exact doses in the chart above. Most formulas can't do that. They're dosed so low that doubling only gets you to adequate, or so high that doubling takes you past safe. We built the headroom in on purpose.

Phosphatidylserine is the one place we sit below the most-studied dose at either tier: 100 mg at two capsules, 200 mg at four, against 300 mg in the trials. We'd rather tell you that than round it up.

The caffeine-masking trick

Perhaps the most cynical practice: using caffeine as the primary active while marketing the product as a sophisticated nootropic. Caffeine reliably increases alertness and reaction time, which are real, measurable effects. But it does not improve learning, long-term memory, or memory consolidation. It creates a feeling of enhancement without the substance of it.

Any legitimate brain supplement should clearly disclose its caffeine content. If a company won't tell you how much is in there, they probably don't want you doing the math.

The Prevagen precedent

In December 2024, the FTC won a landmark case against Quincy Bioscience, makers of Prevagen, one of America's best-selling brain supplements. Its own trial, the "Madison Memory Study," found no significant improvement on any of nine cognitive tasks versus placebo. The study failed. Yet the company advertised Prevagen as "clinically shown" for years, citing that same failed study.

"Clinically studied" vs. "clinically dosed"

"Clinically studied" means an ingredient has appeared in at least one trial somewhere. It says nothing about the dose, results, or study quality. Caffeine is "clinically studied." So is sugar.

"Clinically dosed" means the ingredient is present at the same dose used in trials that showed a positive effect. That's the standard that matters, and the one most supplements fail. Neither term is regulated. The only way to tell the difference: look up the studies and compare trial doses to the label.

The quality-control crisis

Even with the right ingredients at the right doses, there's no guarantee the bottle contains what the label says. A 2010 GAO report found 93% of 40 tested supplements contained trace lead, arsenic, mercury, cadmium, or pesticides. The FDA's Botanical Safety Consortium (2023) found 23% of botanical supplements contained undeclared synthetic compounds. Voluntary quality-certification programs exist to fill this gap, and 96% of products fail their first attempt.

The 7-point evaluation

The bottom line

Brain supplements can work. The evidence for bacopa, citicoline, ashwagandha, and phosphatidylserine is real and growing. But the gap between what science has proven and what the industry sells you is enormous. Most fail not because the science is bad but because the execution is: blends that hide underdosing, caffeine that masks whether anything else works, and a quality system that relies on voluntary compliance.

The companies that get it right are the ones willing to show you everything: every ingredient, every dose, every study, every test result. Transparency isn't a marketing angle. It's the minimum standard for anything you put in your body twice a day.